Ipca Laboratories is an API and finished-dose manufacturer based in India. It holds 52 active US drug master files and 132 valid CEPs. Its filings concentrate with MHRA (UK), US FDA and TMDA (TZ). Its GMP standing is certified by CDSCO (India), MHRA (UK) and EMA, among 6 authorities. Its most recent recorded inspection, by US FDA, closed on 5 December 2025 as VAI. Customs aggregates show $348.3M of exports covering 9,744 molecules to 137 destinations in 2025.
NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.
| Site | FDA FEI |
|---|---|
| Silvassa, United Arab Emirates | Not on file |
| SUNDERLAND, United Kingdom | Not on file |
| Mumbai, India | Not on file |
| PITHAMPUR, India | Not on file |
| GANDHIDHARN-KUTCH, India | Not on file |
| Kutch, India | Not on file |
6 further sites are on record.
| Molecule | Regulators | Docs |
|---|---|---|
| Hydrochlorothiazide | EDQM, SFDA (Saudi Arabia), US FDA | 9 |
| Metoprolol | EDQM, US FDA | 7 |
| Ondansetron | EDQM, SFDA (Saudi Arabia), US FDA | 6 |
| Furosemide | EDQM, SFDA (Saudi Arabia), US FDA | 5 |
| Hydroxychloroquine | EDQM, SFDA (Saudi Arabia), US FDA | 5 |
| Mesalazine | EDQM, US FDA | 5 |
| Telmisartan | EDQM, US FDA | 5 |
| Carvedilol | EDQM, SFDA (Saudi Arabia), US FDA | 4 |
| Chlorthalidone | EDQM, US FDA | 4 |
| Etodolac | EDQM, US FDA | 4 |
| Hydroxyzine | EDQM, US FDA | 4 |
| Losartan Potassium | EDQM | 4 |
| Metformin | EDQM, SFDA (Saudi Arabia), US FDA | 4 |
| Metoclopramide | EDQM, SFDA (Saudi Arabia), US FDA | 4 |
| Propranolol | EDQM, SFDA (Saudi Arabia), US FDA | 4 |
| Allopurinol | EDQM, US FDA | 3 |
| Atenolol | EDQM, US FDA | 3 |
| Atovaquone | EDQM, US FDA | 3 |
| Bisoprolol | EDQM, US FDA | 3 |
| Chloroquine | EDQM, US FDA | 3 |
| Duloxetine | EDQM, US FDA | 3 |
| Famotidine | EDQM, SFDA (Saudi Arabia) | 3 |
| Fluoxetine | EDQM, US FDA | 3 |
| Glimepiride | EDQM, US FDA | 3 |
| Indapamide | EDQM, SFDA (Saudi Arabia) | 3 |
| Meloxicam | EDQM, US FDA | 3 |
| Olanzapine | EDQM, US FDA | 3 |
| Paroxetine | EDQM, SFDA (Saudi Arabia) | 3 |
| Proguanil | EDQM, US FDA | 3 |
| Pyrantel | EDQM, US FDA | 3 |
Also appears on these molecule pages
| Regulator | Filings | GMP certificates |
|---|---|---|
| MHRA (UK) | 112 | 6 |
| US FDA | 76 | 3 |
| TMDA (TZ) | 42 | None |
| DAV (Vietnam) | 41 | None |
| EMA | 36 | 5 |
| MCAZ (ZW) | 24 | None |
| CDSCO (India) | None | 10 |
| FDA (GH) | None | 4 |
| NAFDAC (NG) | None | 2 |
| Year | Revenue | Exports | Destinations |
|---|---|---|---|
| 2026 YTD | Not reported | $56.2M | 96 |
| 2025 | $1.0B | $348.3M | 137 |
| 2024 | $918.7M | $329.8M | 132 |
| 2023 | $754.7M | $336.7M | 136 |
Export figures are customs aggregates. We do not publish the identity of any buyer.
Choose your molecules and target markets. Ipca Laboratories comes back tiered against every other supplier able to file there.
Start for free